Slow responses to standard dose rituximab in immune thrombocytopenic purpura

Por Kelly, Kevin, Gleeson, Mary, Murphy, Philip Thomas
Publicado em 2009

Cost (Non)-Recovery by Platform Technology Facilities in the Bio21 Cluster

Por Gibbs, Gerard, Clark, Stella, Quinn, JulieAnne, Gleeson, Mary Joy
Publicado em 2010

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

Por Gleeson, Mary, Peckitt, Clare, To, Ye Mong, Edwards, Laurice, Oates, Jacqueline, Wotherspoon, Andrew, Attygalle, Ayoma D, Zerizer, Imene, Sharma, Bhupinder, Chua, Sue, Begum, Ruwaida, Chau, Ian, Johnson, Peter, Ardeshna, Kirit M, Hawkes, Eliza A, Macheta, Marian P, Collins, Graham P, Radford, John, Forbes, Adam, Hart, Alistair, Montoto, Silvia, McKay, Pamela, Benstead, Kim, Morley, Nicholas, Kalakonda, Nagesh, Hasan, Yasmin, Turner, Deborah, Cunningham, David
Publicado no Lancet Haematol (2018)

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

Por Russell, Beth, Moss, Charlotte, Papa, Sophie, Irshad, Sheeba, Ross, Paul, Spicer, James, Kordasti, Shahram, Crawley, Danielle, Wylie, Harriet, Cahill, Fidelma, Haire, Anna, Zaki, Kamarul, Rahman, Fareen, Sita-Lumsden, Ailsa, Josephs, Debra, Enting, Deborah, Lei, Mary, Ghosh, Sharmistha, Harrison, Claire, Swampillai, Angela, Sawyer, Elinor, D'Souza, Andrea, Gomberg, Simon, Fields, Paul, Wrench, David, Raj, Kavita, Gleeson, Mary, Bailey, Kate, Dillon, Richard, Streetly, Matthew, Rigg, Anne, Sullivan, Richard, Dolly, Saoirse, Van Hemelrijck, Mieke
Publicado no Front Oncol (2020)